Vulvar Cancer
101
26
35
44
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.9%
6 terminated out of 101 trials
88.0%
+1.4% vs benchmark
13%
13 trials in Phase 3/4
18%
8 of 44 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 44 completed trials
Clinical Trials (101)
DESTINY-PANTUMOUR04
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Intraoperative Microscopic Assessment of Lymph Node Status in Gynecological Malignancies
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
ASk Questions in GYnecologic Oncology (ASQ-GYO)
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
Cisplatin+Pembrolizumab+RT in Vulvar Cancer
Danish Vulva Cancer Recurrence Study
Indocyanine Green for Detection of Sentinel Lymph Nodes In Comparison to ICG Plus Technetium in the Evaluation of Vulvar Squamous Cell Carcinoma
The Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology Study
Cancer Loyalty Card Study 2 (CLOCS-2)
Electrochemotherapy for Recurrent Vulvar Cancer
Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers
Immunotherapy-related CRP Kinetics in Metastatic Gynecological Malignancies
STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide Excision
A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation